Related Experiment Video
Updated: Jan 23, 2026
05:30
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
1.0K
Cancer Proteomics and the Elusive Diagnostic Biomarkers
Ralph A Bradshaw1,2, Hubert Hondermarck3, Henry Rodriguez4
1Department of Physiology and Biophysics, University of California, Irvine, CA, 92697, USA.
Proteomics
|June 8, 2019
Summary
Despite advances in proteomic analysis, validating cancer biomarkers for early detection remains challenging. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) shows promise in overcoming these hurdles for lethal cancers.
Area of Science:
- Biomarker Discovery
- Proteomics
- Cancer Diagnostics
Background:
- Genomic and proteomic technologies have advanced, yet validating cancer biomarkers for early clinical detection remains difficult.
- Proteomic and multi-omic analyses have identified numerous potential biomarkers, but translating these into diagnostics for early cancer detection is problematic.
Purpose of the Study:
- To review the challenges in converting identified cancer biomarkers into clinical early detection diagnostics.
- To highlight the successes and insights gained from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) in addressing these challenges.
- To assess the potential of proteomic analyses for developing diagnostics for early detection of lethal cancers and new therapeutic strategies.
Main Methods:
- Review of progress in genomic and proteomic technologies for biomarker identification.
- Analysis of challenges in the translation of identified biomarkers to clinical diagnostics.
- Examination of the role and successes of the Clinical Proteomic Tumor Analysis Consortium (CPTAC).
Main Results:
- Proteomic analyses, especially combined with other 'omic approaches, are effective in biomarker identification.
- Significant challenges persist in converting identified biomarkers into validated early diagnostic tools for cancer.
- CPTAC has made notable progress in refining analytical steps and providing insights to overcome these diagnostic challenges.
Conclusions:
- The development of clinical diagnostics for early cancer detection, particularly for lethal cancers, is a critical unmet need.
- CPTAC's successes demonstrate a promising path forward for overcoming the obstacles in biomarker validation and diagnostic development.
- Proteomic analyses hold significant potential for advancing early cancer detection and identifying novel therapeutic strategies.
Related Concept Videos
01:33Proteomics
9.4K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
9.4K
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
820
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
820
01:29Appendicitis-II: Diagnostic Studies and Management
541
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
541
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:15Myasthenia Gravis: Diagnostic Tests
2.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.0K
01:19Pericarditis II: Clinical Features and Diagnostic Tests
303
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
303